|Articles|October 7, 2021
Supplements and Featured Publications
- Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease
Advertisement
This publication was funded and developed by United Therapeutics.
This AJMC® Clinical Brief summarizes results of the pivotal study by Aaron Waxman MD, PhD, et al published in The New England Journal of Medicine on the safety and efficacy of inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
DOJ Abandons Olmstead Defense as Texas v Kennedy Advances
2
FDA Expands Tirzepatide Label to Reduce Cardiovascular Risk in Type 2 Diabetes
3
Myasthenia Gravis Linked to Greater Longevity Than Multiple Sclerosis
4
FDA Approves Rusfertide to Treat Erythrocytosis In Polycythemia Vera
5